Latest news and research on all cancers and treatments, updated several times a week
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the U.S. Moreover, nearly 338,000 patients are diagnosed with pancreatic ...
This human trial is an open label, dose escalation study in subjects with breast, lung, or pancreatic cancerat high risk of relapse after surgery and ...
Campaigners for Pancreatic Cancer UK have handed in a petition to Number Ten calling on the government to help protect a life-prolonging drug from ...
... developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue.
While these factors are all related, body weight has the strongest link to cancer. Breast, colon, rectum, endometrial, esophageal, kidney and pancreatic ...
Five year survival rates for cancers of the digestive organs improved from only 10 per cent to 12 per cent, pancreatic cancer from 3.5 per cent to 6.1 per ...
Death rates from some cancers, including pancreatic cancer and kidney cancer, also increased. At the same time, countries have made great strides in ...
“Using the immune system as a weapon against cancer is just now beginning to gain momentum. The results of this study are encouraging as we ...
Chemotherapy for Treatment of Grade II Gliomas
In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas-the three most heavily encountered and studied of the low-grade gliomas.
In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas-the three most heavily encountered and studied of the low-grade gliomas.
(18)F-NaF PET/CT and (11)C-Choline PET/CT for the Initial Detection of Metastatic Disease in Prostate Cancer: Overview and Potential Utilization
We briefly review these two imaging technologies and provide potential utilization strategies for metastatic prostate cancer based on the available data.
We briefly review these two imaging technologies and provide potential utilization strategies for metastatic prostate cancer based on the available data.
Cancer Stem Cells: Implications for Cancer Therapy
This review will focus on properties of cancer stem cells; will compare and contrast the cancer stem cell model with the clonal evolution model of tumorigenesis; will discuss the role of cancer stem cells in the development of resistance to chemotherapy; and will review the therapeutic implications and challenges of targeting cancer stem cells, with an assessment of the potential such an approach holds for improving outcomes for patients with cancer.
This review will focus on properties of cancer stem cells; will compare and contrast the cancer stem cell model with the clonal evolution model of tumorigenesis; will discuss the role of cancer stem cells in the development of resistance to chemotherapy; and will review the therapeutic implications and challenges of targeting cancer stem cells, with an assessment of the potential such an approach holds for improving outcomes for patients with cancer.
Improving Outcomes in Advanced DLBCL: Systemic Approaches and Radiotherapy
In this review, we will first briefly summarize prior attempts to improve outcomes in advanced DLBCL using systemic therapy approaches, and then we will highlight the potential role of RT in advanced DLBCL.
In this review, we will first briefly summarize prior attempts to improve outcomes in advanced DLBCL using systemic therapy approaches, and then we will highlight the potential role of RT in advanced DLBCL.
Commentaries
• Advanced DLBCL: As Systemic Therapy Improves, the Need for RT Diminishes
• Who Should-or Should Not-Receive RT for DLBCL?
• Advanced DLBCL: As Systemic Therapy Improves, the Need for RT Diminishes
• Who Should-or Should Not-Receive RT for DLBCL?
Bone Drugs May Thwart HER-Driven Tumors
Researchers have discovered that bisphosphonates inactivate human epidermal growth factor (EGF) receptors to exert antitumor effects, and they say the widely prescribed osteoporosis drugs may prove to be a cheap and useful adjuvant to current therapies for HER-driven cancers.
FULL STORY»
Immune Checkpoint Tx Takes Down Ca
Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer, particularly in patients with suppressed immune systems that appeared to be "reinvigorated" by the therapy, investigators reported. FULL STORY»
Researchers have discovered that bisphosphonates inactivate human epidermal growth factor (EGF) receptors to exert antitumor effects, and they say the widely prescribed osteoporosis drugs may prove to be a cheap and useful adjuvant to current therapies for HER-driven cancers.
FULL STORY»
Immune Checkpoint Tx Takes Down Ca
Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer, particularly in patients with suppressed immune systems that appeared to be "reinvigorated" by the therapy, investigators reported. FULL STORY»
Year in Review: Progress in Melanoma
After several years of dramatic developments in melanoma therapy, 2014 proved to be a year of incremental growth in understanding the disease process and its clinical management. Melanoma specialists continued to accumulate information about optimizing the use of BRAF inhibitors and other therapies, but immunotherapy made therapeutic inroads in the form of checkpoint inhibitors.
Meanwhile, pathology and epidemiologic studies revealed that superficial melanoma lesions are more ominous than previously recognized.
After several years of dramatic developments in melanoma therapy, 2014 proved to be a year of incremental growth in understanding the disease process and its clinical management. Melanoma specialists continued to accumulate information about optimizing the use of BRAF inhibitors and other therapies, but immunotherapy made therapeutic inroads in the form of checkpoint inhibitors.
Meanwhile, pathology and epidemiologic studies revealed that superficial melanoma lesions are more ominous than previously recognized.
NBI has visualized non-muscle-invasive bladder cancer lesions in an additional 17 percent of patients, as compared to white light. Blue and green ...
The company stated on its third-quarter call that the lead indication for apatorsen is the treatment of bladder cancer. Key survival data from the phase II ...
... clinical trials for a number of cancers, including gastric and bladder cancer, as well as relapsed/refractory classical Hodgkin Lymphoma (cHL).
SAN CARLOS, Calif., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Flexus Biosciences, Inc., a biotechnology company focused on the discovery and ...
The results of this study are encouraging as we gather evidence thatimmunotherapies have the potential to work in many different types of cancer.
A novel therapeutic to fight colon cancer by using the bacteria primarily ... support a human immune system, to test the anti-cancer immunotherapy.
A new strategy for developing drugs to fight cancer and other diseases ... new direction in immunotherapy for treating cancer and other diseases, the ...
Immunological quiescence in the central nervous system (CNS) is a potential barrier to immune mediated anti-tumor response. One suppressive ...
Cancer News in Science Daily
“In addition to DNA damage, cancer depends on the slow degradation of tissue that allows cancer cells to out-compete healthy cells, a new study shows. "We show that mutations, although necessary, cannot promote blood cancer development without an age-altered tissue microenvironment," the researchers write.
“The unique genetic paths that the childhood brain tumor medulloblastoma follows when the disease comes back has been mapped out, researchers report. Scientists looked at biopsies from the relapsed tumours of 29 patients. They found a range of changes that only appeared when the disease returned and were responsible for the cancer becoming more aggressive.
“Researchers have received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue. Their ongoing work may have far-reaching implications, including new ways to treat tissue damaged during a heart attack or stroke, and even a possible cure for cancer.
“Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor growth. Now, researchers have discovered a previously unknown mechanism for regulating programmed cell death. They have also shown that patients with lymphoma often carry mutations in this signal pathway.
“Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery, indicate that prospective randomized trials comparing these two bladder cancer surgeries are warranted.
“The cause of prostate cancer may be linked to Parkinson’s disease through a common enzyme family called sirtuins. Finding an enzyme that regulates this process could provide excellent new prevention approaches for this common malignancy, researchers say. Sirtuin enzymes have been implicated in neurodegeneration, obesity, heart disease, and cancer.
“Airline pilots can be exposed to the same amount of UV-A radiation as that from a tanning bed session because airplane windshields do not completely block UV-A radiation, according to research. Airplane windshields are commonly made of polycarbonate plastic or multilayer composite glass. UV-A radiation can cause DNA damage in cells and its role in melanoma is well known, researchers say.
Tambahkan Komentar